Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01530269 · ClinicalTrials.gov registry record · Phase 2
C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
A Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Phoenix Molecular Imaging.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT01530269: Completed Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Phoenix Molecular Imaging.
NCT01530269 is a Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma that has completed, run by Phoenix Molecular Imaging. The registered enrollment target is 300 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01530269, a Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, has completed, sponsored by Phoenix Molecular Imaging.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. This clinical trial is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments.
Primary Outcome
Patients will undergo needle biopsy of positive metastatic findings on C11- Acetate PET/CT
Conditions Studied
Interventions
- DRUG C11-Sodium Acetate
Study Locations (1)
Arizona
- Phoenix Molecular Imaging - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2012-04 |
| Est. Completion | 2019-01 |
| Phase | Phase 2 |
What the finished NCT01530269 record still lists
NCT01530269 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (51% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which C11-Sodium Acetate is the first listed.
NCT01530269 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT01530269 about?
NCT01530269 is a clinical study titled "C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma". Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. This clinical trial is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments.
What is the current status of trial NCT01530269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2012-04. Estimated completion is 2019-01.
What conditions does trial NCT01530269 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma.
What interventions are being tested in trial NCT01530269?
The interventions under investigation include: C11-Sodium Acetate (DRUG).
Who is sponsoring clinical trial NCT01530269?
This trial is sponsored by Phoenix Molecular Imaging, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01530269 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01530269's enrollment target sits among peer trials
300 159th of 735 higher than 569 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
- NCT01266577 · 300 participants · NA
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia